Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019.

ABSTRACT:

Importance

Despite the political salience of insulin prices, no study to date has quantified trends in insulin prices that account for manufacturer discounts (net prices).

Objective

To describe trends in insulin list prices and net prices faced by payers from 2012 to 2019 and estimate changes in net prices after the 2015 to 2017 entry of new insulin products.

Design, setting, and participants

This longitudinal study included an analysis of Medicare, Medicaid, and SSR Health drug pricing data from January 1, 2012, to December 31, 2019. Data analyses were performed from June 1, 2022, to October 31, 2022.

Exposures

US sales of insulin products.

Main outcomes and measures

Net prices faced by payers were estimated for insulin products as list prices minus man

SUBMITTER: Dickson S 

PROVIDER: S-EPMC10276305 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature